JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.58 2.92

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.36

Max

4.63

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+40.13% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

12M

573M

Eelmine avamishind

1.66

Eelmine sulgemishind

4.58

Uudiste sentiment

By Acuity

50%

50%

177 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. apr 2026, 23:33 UTC

Kuumad aktsiad

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28. apr 2026, 23:24 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28. apr 2026, 22:46 UTC

Tulu

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28. apr 2026, 22:37 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28. apr 2026, 22:15 UTC

Tulu
Uudisväärsed sündmused

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28. apr 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28. apr 2026, 23:19 UTC

Market Talk
Tulu

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28. apr 2026, 23:09 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28. apr 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees One Rate Rise to 4% in Benign Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28. apr 2026, 22:51 UTC

Tulu

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28. apr 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. apr 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28. apr 2026, 22:40 UTC

Market Talk
Uudisväärsed sündmused

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28. apr 2026, 22:32 UTC

Tulu

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28. apr 2026, 22:22 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28. apr 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28. apr 2026, 22:07 UTC

Market Talk
Uudisväärsed sündmused

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

40.13% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  40.13%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

177 / 348 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat